Contact

All Stories

  1. Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease

    Article • PLoS ONE, December 2020, PLOS

    Dr Mark W Douglas

  2. Using a chronic hepatitis B Registry to support population-level liver cancer prevention in Sydney, Australia

    Article • Clinical Epidemiology, December 2017, Dove Medical Press

    Dr Mark W Douglas, chee Khoo

  3. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease

    Article • Scandinavian Journal of Clinical and Laboratory Investigation, July 2017, Taylor & Francis

    Dr Mark W Douglas, Clinical Chair Professor Henning Gronbaek, professor adrian bauman

  4. A systematic review and meta-analysis of HCV clearance

    Article • Liver International, March 2017, Wiley

    Dr Mark W Douglas

  5. Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals’ perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion

    Article • Journal of Health Psychology, September 2016, SAGE Publications

    Dr Mark W Douglas

  6. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes

    Article • Hepatology, March 2016, Wiley

    Dr Mark W Douglas

  7. Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals’ perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion

    Article • Journal of Health Psychology, February 2016, SAGE Publications

    Dr Mark W Douglas

  8. IKK-alpha mediates Hepatitis C Virus induced Lipid Accumulation

    Article • Hepatology, February 2014, Wolters Kluwer Health

    Dr Mark W Douglas